26Dec/13

Envarsus Designated Orphan Drug for Kidney Transplant Rejection Prophylaxis – Monthly Prescribing Reference

Immunosuppressive Drugs

Envarsus Designated Orphan Drug for Kidney Transplant Rejection Prophylaxis
Monthly Prescribing Reference
… Drug for Kidney Transplant Rejection Prophylaxis. Veloxis announced that the FDA has granted Orphan Drug designation to Envarsus (tacrolimus; formerly LCP-Tacro) for prophylaxis of organ rejection in patients receiving allogenic kidney transplants.
FDA grants orphan drug designation to Veloxis’ kidney transplant drugPharmaceutical Business Review

all 3 news articles »
24Dec/13

Veloxis Pharmaceuticals Envarsus(R) Granted Orphan Drug Status by US Food … – Wall Street Journal

Immunosuppressive Drugs

Veloxis Pharmaceuticals Envarsus(R) Granted Orphan Drug Status by US Food …
Wall Street Journal
The designation is to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases. Envarsus(R) is Veloxis’ once-daily formulation of tacrolimus employing the company’s proprietary MeltDose(R) technology.

and more »